Ms. Dalton is currently a Senior Managing Partner at Pfizer Ventures and Vice President, Global Business Development at Pfizer Inc. Since joining Pfizer in 2007, she has led Pfizer’s efforts to deploy capital to generate both financial returns and strategic opportunities for the company. Under the leadership of Dr Dalton, Pfizer Ventures has invested more than $ 700 million in more than 90 portfolio company investments, making Pfizer Ventures one of the leading corporate venture capital groups in the life sciences industry. Barbara is currently a board member of the following Pfizer Ventures portfolio companies: Artios, Cydan, IMARA, Ixchelsis and Second Genome.
Following his doctorate. of Pennsylvania Medical College (now Drexel University School of Medicine), Dalton’s pharmaceutical career began in immunology at Smith Kline & French Research Laboratories. She joined their venture capital group, SR One, Limited, where she spent ten years developing her venture capital expertise. In 2000, Ms. Dalton also became general partner of private venture capital fund EuclidSR Partners, a position she held until joining Pfizer in 2007.
“We are delighted to expand our board of directors with Barbara, who will bring an impressive level of pharmaceutical expertise and critical insights to our work.” mentionned Eric Converse, CEO of AMRA. “We are a growing company and the opportunities ahead are enormous. Having Barbara on board brings an added level of confidence and calculated thinking which I believe will help guide and accelerate our innovations and business plans. “
About AMRA Medical
AMRA is a digital health company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition assessment, the ability to automatically produce multiple fat and muscle biomarkers with unparalleled precision and precision, as well as contextual disease information – all at from a single rapid MRI of the whole body.
SOURCE AMRA Medical